2.705USD-0.55%Mkt Cap: 90.19M USDP/E: —Last update: 2026-06-01
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a ch…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap90.19M USD
Enterprise Value75.29M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.93M USD
Revenue/Share—
Last Price2.705 USD
Fiscal Year EndOct 2025
MR QuarterJan 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS03528H1095
Valuation
P/E (Trailing)—
P/E (Forward)-7.50
PEG-0.11
EV/EBITDA—
EV/Revenue—
P/S—
P/B5.99
EPS (TTM)-0.32
EPS (Forward)-0.36
52W Range
2.4409% of range5.460
52W High5.460 USD
52W Low2.440 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-72.07%
ROA-67.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.17M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-3.87%
Net Debt-14.01M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio12.18
Quick Ratio11.49
Book Value/Sh0.4510 USD
Cash/Share0.4240 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJun 26, 2015
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)11.00 USD
Target Range9.000 USD – 14.00 USD
# Analysts3
Ownership
Shares Out.33.53M
Float31.72M
Insiders5.38%
Institutions15.41%
Short Interest
Short Ratio8.3d
Short % Float3.10%
Short % Out.2.93%
Shares Short983.35K
Short (prev mo.)1.04M
Technical
SMA 502.820 (-4.1%)
SMA 2003.336 (-18.9%)
Beta0.65
S&P 52W Chg27.94%
Avg Vol (30d)108.75K
Avg Vol (10d)96.83K
Technical Indicators
RSI (14)43.0
MACD-0.0566
MACD Signal-0.0342
MACD Hist.-0.0225
BB Upper3.165 USD
BB Middle2.868 USD
BB Lower2.570 USD
BB Width20.76%
ATR (14)0.1340 USD
Vol Ratio (20d)0.77x